Advertisement

Topics

Nabi Biopharmaceuticals Company Profile

05:33 EDT 24th September 2018 | BioPortfolio

NABI Biopharmaceuticals are a biopharmaceutical company focused on the development of products that address unmet medical needs in the areas of nicotine addiction and infectious disease. We leverage our experience and knowledge in powering the human immune system to target serious medical conditions in these areas. Our lead products in development are NicVAX® [ Nicotine Conjugate Vaccine ], an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and StaphVAX® [ Staphylococcus aureus Vaccine ], a new pentavalent vaccine designed to prevent S.aureus infections including those infections caused by the most dangerous antibiotic-resistant strains of S.aureus .

NicVAX is an investigational vaccine based on patented technology. Nicotine, a small molecule, can cross the blood-brain barrier and reach specific receptors in the brain, thereby leading to the highly addictive pleasure sensation experienced by smokers and users of nicotine products. NicVAX is designed to stimulate the immune system to produce antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier, and thus is unable to reach the receptors in the brain and trigger pleasure sensations. In November 2007, we announced the successful completion of a Phase IIb “proof-of-concept” clinical trial for our NicVAX development program. The Phase IIb study showed statistically significant rates of smoking cessation and continuous long-term smoking abstinence at 6 and 12 months for subjects injected with NicVAX as compared with subjects injected with a placebo.

StaphVAX is an investigational vaccine based on patented technology, including technology that we have licensed on an exclusive basis from the National Institutes of Health, or NIH. We are developing StaphVAX for use in patients who are at high risk of S.aureus infection and who are able to respond to a vaccine by producing their own antibodies.

NicVAX and StaphVAX will require additional development, including preclinical testing and human studies for StaphVAX and additional human testing for NicVAX as well as regulatory approvals, before we can market them. We are continuing to develop NicVAX and StaphVAX while we search for partners who will assist in the further development and commercialization of these products.

Location

12276 Wilkins Ave
Rockville
MD
20852
United States of America

Contact

Phone: 301-255-6803
Fax: 301-770-3097
Email: gfries@nabi.com


News Articles [203 Associated News Articles listed on BioPortfolio]

Emergent BioSolutions' (EBS) CEO Dan Abdun Nabi on Q1 2018 Results - Earnings Call Transcript

ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership

RAMSEY, N.J. and BOCA RATON, Fla., April 24, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), today announced that it has successfully completed the ...

Emergent BioSolutions, Inc (EBS) CEO Dan Abdun Nabi on Q2 2018 Results - Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) CEO Dan Abdun-Nabi on Acquisition of Adapt Pharma and its Flagship Product NARCAN Nasal Spray Conference Call (Transcript)

Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene's Virus-Based Immunotherapies TG6002 and TG1050 in Greater China

Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares Deals give Tasly Biopharmaceuticals full control over Greater China1 development and commercial rights to the...

Akebia Therapeutics to merge with Keryx Biopharmaceuticals

US-based biopharmaceutical firm Akebia Therapeutics has signed a definitive agreement to merge with Keryx Biopharmaceuticals to form a fully integrated...Read More... The post Akebia Therapeutics to m...

Eiger BioPharmaceuticals completes enrolment in Prevent trial

Eiger BioPharmaceuticals has completed patient enrolment in the Phase ll Prevent trial evaluating the safety and durability of subcutaneous (SC)...Read More... The post Eiger BioPharmaceuticals comple...

5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmaceuticals Leads with 81.62 Percent

Eiger BioPharmaceuticals, Arqule, Galectin Therapeutics, MEI Pharma and BioDelivery Sciences were last week's top gainers on the NASDAQ. The post 5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmace...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Nabi-hb [Biotest Pharmaceuticals Corporation]

Hepatitis B Immune Globulin (Human) Nabi-HB Solvent Detergent Treated and Filtered

Nabi-hb [Biotest Pharmaceuticals Corporation]

Hepatitis B Immune Globulin (Human) Nabi-HB Solvent Detergent Treated and Filtered

Thrombin human [Ethicon, Inc]

These highlights do not include all the information needed to use EVITHROM safely and effectively. See full prescribing information for EVITHROM.EVITHROM, Thrombin, Topical (Human)For Topical Use Only...

PubMed Articles [40 Associated PubMed Articles listed on BioPortfolio]

Video Comment on Zaheer Nabi et al.

Surfactants as Stabilizers for Biopharmaceuticals: An Insight into the Molecular Mechanisms for Inhibition of Protein Aggregation.

Surfactants are common stabilizers, often added to biopharmaceuticals formulations, but the mechanisms at the basis of their activity are unclear. The aim of this work is to provide insight into the m...

Next Generation Biopharmaceuticals: Product Development.

Therapeutic proteins show a rapid market growth. The relatively young biotech industry already represents 20 % of the total global pharma market. The biotech industry environment has traditionally bee...

Characterisation of protein aggregation with the Smoluchowski coagulation approach for use in biopharmaceuticals.

Protein aggregation is a field of increasing importance in the biopharmaceutical industry. Aggregated particles decrease the effectiveness of the drug and are associated with other risks, such as incr...

Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection.

Physicochemical and structural properties of proteins used as active pharmaceutical ingredients of biopharmaceuticals are determinant to carry out their biological activity. In this regard, the assays...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Open Label Phase 3 Study of NABI-IGIV 10% [(HUMAN)] In Subjects With Primary Immune Deficiency Disorders (PIDD)

The purpose of this study is to determine if NABI-IGIV (10%) is safe and effective in preventing serious bacterial infections in the treatment of patients with primary immune deficiency di...

Nicotine Vaccination and Nicotinic Receptor Occupancy

This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharm...

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children. In China, The overall impact of Hib-related infect...

Companies [186 Associated Companies listed on BioPortfolio]

Nabi Biopharmaceuticals

NABI Biopharmaceuticals are a biopharmaceutical company focused on the development of products that address unmet medical needs in the areas of nicotine addiction and infectious disease. We leverage o...

Itero Biopharmaceuticals, Inc.

Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical an...

Bechtel Group Biopharmaceuticals Production

Design, construction, and validation of facilities for production of human biopharmaceuticals utilizing either fermentation or cell culture, facilities maintenance & operation for the virtual organiza...

BioRexis Pharmaceutical Corporation

BioRexis™ develops and produces novel biopharmaceuticals with superior pharmacology using efficient manufacturing systems. Many biopharmaceuticals face difficulties in development and commercializat...

Inspiration Biopharmaceuticals, Inc.

Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and improve the treat...

More Information about "Nabi Biopharmaceuticals" on BioPortfolio

We have published hundreds of Nabi Biopharmaceuticals news stories on BioPortfolio along with dozens of Nabi Biopharmaceuticals Clinical Trials and PubMed Articles about Nabi Biopharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nabi Biopharmaceuticals Companies in our database. You can also find out about relevant Nabi Biopharmaceuticals Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record